Tamoxifen May Boost PI3K Signaling to Increase Uterine Cancer Risk in Patients With Breast Cancer
Concurrent treatment with PI3K pathway inhibitors may benefit at-risk patients SAN ANTONIO – Uterine cancers that developed in patients...
Sacituzumab Govitecan-hziy Led to Similar Progression-free Survival as Standard of Care for Certain Endocrine Therapy-refractory Advanced Breast Cancers
SAN ANTONIO – Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they...
Some Breast Cancer Survivors May Safely De-escalate Mammography Three Years After Surgery
SAN ANTONIO – Women 50 or older who de-escalated to less-frequent mammography three years after curative surgery for early-stage...
Neoadjuvant Endocrine Therapy May Elicit Differential Responses in Black vs. White Women with Breast Cancer
PHILADELPHIA – Black women treated with neoadjuvant endocrine therapy for breast cancer were more likely to benefit than white...
Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer
SAN ANTONIO — Data from six-year analysis of the APHINITY trial showed that adding pertuzumab to the previous standard of trastuzumab...
Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Using Genomics to Match Treatments Improved Outcomes for Certain Patients With Metastatic Breast Cancer
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
Camizestrant May Be Superior to Fulvestrant in Patients With Hormone Receptor-positive, HER2-negative Breast Cancer
SAN ANTONIO – The next-generation selective estrogen receptor degrader (SERD) camizestrant improved progression-free survival, compared with fulvestrant (Faslodex), in...
HR-positive, HER2-negative Breast Cancer Patients With High Risk of Recurrence May Benefit From Addition of Anthracyclines to Taxane- based Chemotherapy
Genomic testing helped identify which patients with node-negative, HR-positive, HER2- negative breast cancer could benefit from the addition of...
Chronic Stress May Impact Treatment Completion and Survival Outcomes in Patients with Breast Cancer
PHILADELPHIA – Elevated allostatic load was associated with a lower likelihood of completing chemotherapy and a lower overall survival...
Novel Endocrine Therapy Giredestrant Improves Disease-free Survival Over Standard of Care for Patients With Early-stage Breast Cancer in Phase III lidERA Trial
SAN ANTONIO – The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant...
ZEST Trial Offers Insights for Using ctDNA to Predict Breast Cancer Recurrence
The study was terminated early due to low detection of ctDNA after treatment among patients with stage 1 to...
Axillary Radiotherapy and Lymph Node Surgery Yielded Comparable 10-year Outcomes for Patients with Breast Cancer
“SAN ANTONIO – Patients with early-stage breast cancer who had cancer detected in a sentinel lymph node biopsy had...
Next-generation PARP Inhibitor Demonstrates Clinical Benefit in Patients with Homologous Recombination Repair-deficient Breast Cancer
Drug has higher selectivity for PARP1, improving safety and tolerability SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP...
AACR Mourns the Loss of Charles A. Coltman Jr., Cofounder of the San Antonio Breast Cancer Symposium
Charles A. Coltman Jr., MD, a cofounder of the San Antonio Breast Cancer Symposium (SABCS) and a longtime member...
AACR Announces Recipients of its 2022 Scientific Achievement Awards and Lectureships
Awardees to be recognized at the AACR Annual Meeting 2022 in New Orleans PHILADELPHIA — The American Association for...
Black Patients With Triple-negative Breast Cancer May Be Less Likely to Receive Immunotherapy Than White Patients
Among patients who received immunotherapy, outcomes were similar between Black and white patients LOS ANGELES – In recent years,...
Six Factors May Predict Invasive Breast Cancer Recurrence after Ductal Carcinoma in Situ Diagnosis
PHILADELPHIA – Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in...
Delaying Adjuvant Chemotherapy Associated With Worse Outcomes for Patients With Triple-negative Breast Cancer
“SAN ANTONIO – Patients with triple-negative breast cancer who delayed starting adjuvant chemotherapy for more than 30 days after...
Lifestyle Intervention Helped Breast Cancer Survivors Lose Weight, and Was Associated with Higher Disease-free Survival Rates
SAN ANTONIO – Survivors of early-stage breast cancer who participated in a lifestyle intervention on healthy habits lost weight...
New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1
SAN ANTONIO — The investigational HER2-targeted antibody-drug conjugate [Fam-] trastuzumab deruxtecan (T-DXd) demonstrated durable objective responses in patients with...
Next-generation SERD Protects Against Progression in Some Patients With Advanced Breast Cancer Resistant to Standard Hormone Therapy
Imlunestrant was effective in combination with abemaciclib, and as monotherapy in ESR1-mutated breast cancer SAN ANTONIO – Imlunestrant, an investigational...
Multimodal Machine Learning Model Effective at Predicting Response to CDK4/6 Inhibitors in HR-positive, HER2-negative Breast Cancer Patients
Combining real-world clinical and genomic data resulted in a more accurate prediction of outcomes compared to examining clinical and...
A Genomic Assay May Predict Long-term Prognosis in Premenopausal Patients With Hormone Receptor-positive Early-stage Breast Cancer
Assay can also help identify patients who may benefit from ovarian suppression therapy SAN ANTONIO – Among premenopausal women...
T-DXd Yields Longer Overall Survival than T-DM1 in Patients with HER2-positive Metastatic Breast Cancer
SAN ANTONIO – Second-line treatment with trastuzumab deruxtecan (T-DXd) led to significantly longer overall survival compared with trastuzumab emtansine...
Benefits of Pre-surgical Immunotherapy Were Independent of Race in Patients with Aggressive Breast Cancer
Outcomes were similar between Black patients and patients of other races PHILADELPHIA – Treatment outcomes were similar between Black...
Adjuvant Capecitabine Did Not Significantly Improve Outcomes for Patients With Early-stage Triple-negative Breast Cancer
Subgroup analysis suggested the treatment may benefit patients with nonbasal-like disease SAN ANTONIO Treating patients who had early-stage triple-negative...
Investigational Therapy Pyrotinib with Chemotherapy May Improve Outcomes in Patients with Pretreated HER2-positive Breast Cancer
SAN ANTONIO – Among patients with previously treated HER2-positive metastatic breast cancer, those who received pyrotinib plus capecitabine had...
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Treatment for metastatic disease may last indefinitely, amplifying the need for effective interventions SAN ANTONIO – Among patients with...
Adding Capivasertib to Fulvestrant Improves Progression-free Survival in Patients With Advanced Hormone Receptor-positive Breast Cancer
SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational...